PharmaPoint: Alzheimer’s Disease - France Drug Forecast and Market Analysis to 2022
London (PRWEB) November 21, 2013 -- PharmaPoint: Alzheimer’s Disease - France Drug Forecast and Market Analysis to 2022
Summary
GlobalData has released its new Country report, “PharmaPoint: Alzheimer’s Disease - France Drug Forecast and Market Analysis to 2022”. There are no long-term effective therapies for Alzheimer’s Disease (AD), so this remains at the top of the list for unmet needs. While physicians agree that symptomatic therapies are relatively safe and effective, these therapies are still lacking because of they cannot maintain their effects and lack mechanisms that alter the course of the disease.
France has established specialized AD facilities that have made diagnosis much easier in the rural areas of the country. Moreover, accessibility to affordable medications in France is among the highest of the EU countries. However, there is an widespread notion among family physicians in the EU that referral of an AD patient to specialists is sometimes not in the best interest of their patient, which prevents patients from proceeding along the usual pathway to the most effective management.
Scope
-Overview of Alzheimer’s Disease, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
-Detailed information on the key drugs in France including product description, safety and efficacy profiles as well as a SWOT analysis.
-Sales forecast for the top drugs in France from 2012-2022.
-Analysis of the impact of key events as well the drivers and restraints affecting France Alzheimer’s Disease market.
Reasons to buy
-Understand and capitalize by identifying products that are most likely to ensure a robust return
-Stay ahead of the competition by understanding the changing competitive landscape for Alzheimer’s Disease
-Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
-Make more informed business decisions from insightful and in-depth analysis of drug performance
-Obtain sales forecast for drugs from 2012-2022 in France
Table of Contents
1 Table of Contents 5
1.1 List of Tables 9
1.2 List of Figures 11
2 Introduction 12
2.1 Catalyst 12
2.2 Related Reports 13
3 Disease Overview 15
3.1 Etiology and Pathophysiology 16
3.1.1 Etiology 16
3.1.2 Pathophysiology 19
3.2 Symptoms 31
4 Disease Management 33
4.1 Diagnosis 33
4.1.1 Probable Alzheimer’s Disease Dementia 34
4.1.2 Possible AD Dementia 35
4.1.3 Probable AD Dementia with Evidence of AD Pathophysiological Process 35
4.1.4 Possible Alzheimer’s Dementia with Evidence of the Alzheimer’s Disease Pathophysiological Process 36
4.1.5 Preclinical AD 36
4.1.6 Mild Cognitive Impairment 37
4.2 Treatment Overview 39
4.3 France 42
4.3.1 Diagnosis 42
4.3.2 Clinical Practice 42
5 Competitive Assessment 44
5.1 Overview 44
5.2 Strategic Competitor Assessment 44
5.3 Product Profiles - Major Brands 47
5.3.1 Aricept (donepezil hydrochloride) 47
5.3.2 Exelon (rivastigmine, rivastigmine tartrate) 51
5.3.3 Razadyne (galantamine hydrobromide) 56
5.3.4 Namenda (memantine hydrochloride) 60
6 Opportunity and Unmet Need 64
6.1 Unmet Needs Overview 64
6.1.1 Public Awareness 66
6.1.2 Specialized Institutions at Local Levels 67
6.1.3 Screening and Diagnosis 67
6.1.4 Early Intervention 68
6.1.5 Improved Clinical Trial Design 69
6.1.6 Effective Therapy 70
6.1.7 Behavioral Treatments 71
6.2 Gap Analysis 71
6.2.1 Disease Prevention 72
6.2.2 Diagnosis from Biomarkers 73
6.2.3 Behavioral Therapies 74
7 Pipeline Assessment 75
7.1 Overview 75
7.2 Early-Stage Pipeline Assessment 75
7.3 AD Pipeline by Mechanism of Action 77
7.4 Enzymatic Processing 78
7.5 Immunization 79
7.6 Anti-Aggregation 79
7.7 “Me-Too” 80
7.8 Novel Therapeutic Approaches 81
7.9 Technology Trends Analytic Framework 81
7.10 Promising Drugs in Clinical Development 82
7.10.1 Arimenda 84
7.10.2 Solanezumab 87
7.10.3 Gantenerumab 91
7.10.4 Crenezumab 95
7.10.5 TRx0237 99
7.10.6 MK-8931 102
7.10.7 EVP-6124 105
7.10.8 Lu AE58054 108
8 Market Outlook 112
8.1 France 112
8.1.1 Forecast 112
8.1.2 Key Events 116
8.1.3 Drivers and Barriers 116
9 Appendix 120
9.1 Bibliography 120
9.2 Abbreviations 131
9.3 Methodology 137
9.4 Forecasting Methodology 137
9.4.1 Diagnosed AD patients 137
9.4.2 Percent Drug-treated Patients 138
9.4.3 Drugs Included in Each Therapeutic Class 138
9.4.4 Launch and Patent Expiry Dates 139
9.4.5 General Pricing Assumptions 140
9.4.6 Individual Drug Assumptions 141
9.4.7 Generic Erosion 146
9.4.8 Pricing of Pipeline Agents 146
9.5 Physicians and Specialists Included in this Study 148
9.6 About the Authors 149
9.6.1 Author 149
9.6.2 Global Head of Healthcare 150
9.7 About GlobalData 151
9.8 Disclaimer 151
List of Tables
Table 1:Symptoms of AD 32
Table 2:Guidelines for the Treatment of AD 39
Table 3:Most Prescribed Drugs for AD by Class in the Global Markets, 2012 40
Table 4:Leading Branded Treatments for AD, 2013 45
Table 5:Product Profile - Aricept 48
Table 6:Aricept SWOT Analysis, 2013 51
Table 7:Product Profile- Exelon 52
Table 8:Exelon SWOT Analysis, 2012 55
Table 9:Product Profile - Razadyne 57
Table 10:Razadyne SWOT Analysis, 2013 59
Table 11:Product Profile- Namenda 61
Table 12:Namenda SWOT Analysis, 2013 63
Table 13:Overall Unmet Needs - Current Level of Attainment 65
Table 14:Clinical Unmet Needs - Gap Analysis, 2013 72
Table 15:Technology Trends Analytic Framework for the AD Pipeline, 2012 82
Table 16:Comparison of Therapeutic Classes in Development for AD, 2013 82
Table 17:Comparison of Therapeutic Classes in Development for AD, 2013 83
Table 18:Product Profile - Arimenda 84
Table 19:Arimenda SWOT Analysis, 2013 86
Table 20:Product Profile - Solanezumab 87
Table 21:Solanezumab SWOT Analysis, 2013 90
Table 22:Product Profile - Gantenerumab 91
Table 23:Gantenerumab SWOT Analysis, 2013 95
Table 24:Product Profile - Crenezumab 96
Table 25:Crenezumab SWOT Analysis, 2013 98
Table 26:Product Profile - TRx0237 99
Table 27:TRx0237 SWOT Analysis, 2013 101
Table 28:Product Profile - MK-8931 102
Table 29:MK-8931 SWOT Analysis, 2013 105
Table 30:Product Profile - EVP-6124 106
Table 31:EVP-6124 SWOT Analysis, 2013 108
Table 32:Product Profile - Lu AE58054 109
Table 33:Lu AE58054 SWOT Analysis, 2013 111
Table 34:Sales Forecasts ($m) for AD in France, 2012-2022 114
Table 35:Key Events Impacting Sales for AD in France, 2012-2022 116
Table 36:AD Market in France - Drivers and Barriers, 2012-2022 116
Table 37:Key Launch Dates 139
Table 38:Key Patent Expirations 140
List of Figures
Figure 1:Atrophy of the Brain in AD 21
Figure 2:Key Pathological Features in AD Versus a Healthy Neuron 23
Figure 3:Non-Amyloidogenic Metabolism of APP 25
Figure 4:Amyloidogenic Metabolism of APP 26
Figure 5:Neurofibrillary Tangles 28
Figure 6:Oxidative Damage Due to Free Radicals 30
Figure 7:Strategic Competitor Assessment of the Marketed Products in AD, 2013 46
Figure 8:AD - Pipeline Drugs by Target, 2012 76
Figure 9:Competitive Assessment of Late-Stage Pipeline Agents in AD, 2012-2022 83
Figure 10:Sales for AD in France by Drug Class, 2012-2022 115
Read the full report:
PharmaPoint: Alzheimer’s Disease - France Drug Forecast and Market Analysis to 2022
For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +44 208 816 85 48
Website: http://www.reportbuyer.com
Sarah Smith, Research Advisor at Reportbuyer.com, +44 208 816 85 48, [email protected]
Share this article